Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review
This real-world analysis indicates that temozolomide is feasible and associated with disease stabilization in selected patients, while bevacizumab-based combinations showed signals of clinical activity in recurrent adult ependymomas. Prospective, biomarker-driven multicenter trials are warranted to optimize systemic strategies in this rare disease.
Authors
- Giovanna Pintacuda
- Marta Padovan (ORCID: https://orcid.org/0000-0001-7362-3127)
- Angela Guerriero (ORCID: https://orcid.org/0000-0001-9981-7448)
- Luisa Bellu (ORCID: https://orcid.org/0000-0002-7286-4014)
- SARA LONARDI (ORCID: https://orcid.org/0000-0002-7593-8138)
- Franco Chioffi
- Giovanni Librizzi (ORCID: https://orcid.org/0000-0002-2409-457X)
- Marta Maccari
- Alba Fiorentino
- Francesco Volpin
- Alberto Bosio
- Mario Caccese
- Giuseppe Lombardi
- Luca Denaro
- Tamara Ius
Institutions
- Luminex (United States) (US)
- University of Padua (IT)
- Lahore University of Management Sciences (PK)
- Istituto Oncologico Veneto (IT)
- Ospedale Generale Regionale Francesco Miulli (IT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-18
- DOI
- https://doi.org/10.3389/fonc.2026.1748353
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute